A5009135089- Hepatocellular Carcinoma Treatment and Prognosis
- Liver Disease Diagnosis and Treatment
- Hepatitis B Virus Studies
- Hepatitis C virus research
- Radiomics and Machine Learning in Medical Imaging
- Appendicitis Diagnosis and Management
- Dialysis and Renal Disease Management
- Frailty in Older Adults
- Colorectal Cancer Treatments and Studies
- Pancreatic and Hepatic Oncology Research
- Liver Disease and Transplantation
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Nutrition and Health in Aging
- Cancer Mechanisms and Therapy
- Organ Transplantation Techniques and Outcomes
- Clostridium difficile and Clostridium perfringens research
- Renal cell carcinoma treatment
- Liver Diseases and Immunity
- Viral gastroenteritis research and epidemiology
- Central Venous Catheters and Hemodialysis
- Pediatric Hepatobiliary Diseases and Treatments
- Folate and B Vitamins Research
- Pancreatic function and diabetes
- Lung Cancer Diagnosis and Treatment
- Cancer Immunotherapy and Biomarkers
Seoul National University Hospital
2020-2024
Seoul National University
2019-2022
Seoul National University Bundang Hospital
2021
Abstract The treatment decisions for patients with hepatocellular carcinoma are determined by a wide range of factors, and there is significant difference between the recommendations widely used staging systems actual initial choices. Herein, we propose machine learning-based clinical decision support system suitable use in multi-center settings. We collected data from nine institutions South Korea training validation datasets. internal external datasets included 935 1750 patients,...
Background/Aims: Several treatment options are currently available for patients with hepatocellular carcinoma (HCC) failing previous sorafenib treatment. We aimed to compare the effectiveness of regorafenib and nivolumab in these patients.Methods: Consecutive HCC who received or after failure were included. Primary endpoint was overall survival (OS) secondary endpoints time progression, tumor response rate, adverse events. Inverse probability weighting (IPTW) using propensity score conducted...
Objective Direct comparison of the clinical outcomes between nucleos(t)ide analogue (NA) discontinuation versus NA continuation has not been performed in patients with chronic hepatitis B who achieved HBsAg-seroclearance. Whether was as safe after NA-induced surface antigen HBV (HBsAg) seroclearance investigated present study. Designs This multicentre study included 276 from 16 hospitals Korea HBsAg seroclearance: 131 (47.5%) discontinued treatment within 6 months (NA group) and 145 (52.5%)...
Abstract Background & Aims There is no proven treatment for ursodeoxycholic acid (UDCA)‐refractory primary biliary cholangitis (PBC) other than obeticholic acid. Although fibrates have been reported to improve biochemical parameters, the long‐term effects remain unclear. This study evaluated effect of fibrate on clinical outcomes UDCA‐refractory PBC. Methods Patients whose alkaline phosphatase (ALP) was not normalized with at least 13 mg/kg UDCA >1 year were included from two tertiary...
Hepatocellular carcinoma (HCC) can develop among chronic hepatitis B patients after surface antigen (HBsAg) seroclearance. However, whether HCC risk HBsAg seroclearance differs between antiviral therapy (AVT)-induced or spontaneous cases and ways to identify at-risk populations remain unclear.A retrospective cohort of 1,200 adult who achieved (median age: 56 years; 824 men; 165 with cirrhosis; 216 AVT-induced cases) were analyzed. The the performance 6 prediction models assessed.During a...
Both trans-arterial radioembolization (TARE) and conventional chemoembolization (TACE) can effectively control hepatocellular carcinoma (HCC) in patients who are not suitable for curative resection. This study compared the effectiveness of TARE TACE as initial treatment assessed by tumor response clinical outcomes.Data were retrospectively analyzed propensity score-matched cohort overall survival (OS), progression-free (PFS), intrahepatic PFS have received or first HCC from March 2012 to...
Abstract Objective The study aimed to investigate the effect of body composition changes during chemotherapy on clinical outcomes in patients with pancreatic cancer. Results In locally advanced cancer (LAPC), cross-sectional area skeletal muscle (SM) and adipose tissue (AT) at level third lumbar vertebra was measured. SM AT ratios indicated chemotherapy. were classified into three groups based these ratios: group 1, ≥ 1.00; 2, 0.85–0.99; 3, < 0.85. overall survival (OS) surgical resection...
It remains controversial whether surgical resection, compared to radiofrequency ablation (RFA), improves overall survival (OS) in patients with early hepatocellular carcinoma (HCC). This study aimed compare OS after RFA that resection for HCC. retrospective included who underwent or as initial treatment hepatitis B virus (HBV)-related HCC at a very stage. A total of 761 (RFA, n = 194; 567) from Seoul National University Hospital (Seoul, South Korea) and 1277 352; 925) the Korean Primary...
Still in real-world practice, advanced hepatocellular carcinoma (HCC) patients are treated with transarterial chemoembolization (TACE). This study compared the therapeutic effectiveness of initial TACE treatment and sorafenib HCC patients.Advanced initially or were included this study. Treatment crossover due to an unfavorable response was allowed. Propensity score (PS) matching applied for balancing baseline characteristics. The primary outcome overall survival (OS) secondary outcomes tumor...
Abstract Objective: The study aimed to investigate the effect of body composition changes during chemotherapy on clinical outcomes in patients with pancreatic cancer. Results: In locally advanced cancer (LAPC), cross-sectional area skeletal muscle (SM) and adipose tissue (AT) at level third lumbar vertebra was measured. SM AT ratios indicated chemotherapy. were classified into three groups based these ratios: group 1, ≥1.00; 2, 0.85-0.99; 3, <0.85. overall survival (OS) surgical resection...